Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's demand for confidential data.
The decision was revealed following a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official representative has since clarified that the United States was demanding access to health data for research and commercial gain while refused to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued negotiations to secure a agreement agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Context
This development follows a comparable situation in Kenya, where a court blocked a related health funding agreement after concerns were raised about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral deals to boost openness and accountability.
According to reports, 16 African countries have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the final treatments would be available to our citizens if a future health crisis emerge."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were disrupting structures already set up through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to deal with future pandemics.
"This framework is intended to ensure that when a country provides its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how subsequent collaboration might be designed in a manner that respects the independence and interests of each country."
Health Experts Response
Medical experts expressed it recognised the government's concerns, but recommended that negotiations must proceed given that a large portion of the country's Aids initiatives relied on foreign aid.
"If specific concerns exist, including those involving information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it said.
This impasse emphasises the complex challenges between accepting crucial international aid and safeguarding a country's data in an increasingly data-driven world.